Plain language summary of a publication: the effects of vicadrostat given with or without empagliflozin for treatment of chronic kidney disease
Abstract
Who should read this plain language summary? This article may help people with chronic kidney disease, their families and other caregivers, patient advocates, and healthcare professionals to understand the effects of taking vicadrostat, given with or without empagliflozin, in people with chronic kidney disease. What is chronic kidney disease? Chronic kidney disease (or CKD) is a condition where the kidneys are damaged and cannot filter blood properly. The most common causes of CKD are diabetes and hypertension. CKD varies in its severity and usually gets worse over time. CKD can progress to kidney failure in the most severe cases, although this does not happen in everyone with CKD. Further information on CKD, its diagnosis, and treatment options are shown below. Where can I find more information on CKD? National Institute of Diabetes and Digestive and Kidney Diseases (US): https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd National Institute of Diabetes and Digestive and Kidney Diseases (US; Spanish language): https://www.kidney.org/es/kidney-topics/pruebas-para-revisar-la-salud-renal National Kidney Foundation (US): https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd Kidney Care (UK): https://kidneycareuk.org/kidney-disease-information/kidney-conditions/ckd-chronic-kidney-disease/.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.